As fears mount over a potential new Ebola outbreak, researchers are racing to develop three novel vaccines targeting the Bundibugyo species of the virus. The International Aids Vaccine Initiative (IAVI) has taken the lead in this initiative, warning that the current outbreak poses a significant risk, with nearly 250 lives already claimed. The situation is exacerbated by over 1,000 suspected cases reported in the Democratic Republic of Congo (DR Congo) and nine confirmed cases identified in neighbouring Uganda.
Growing Threat of Ebola
Historically, Ebola outbreaks have been devastating, with the 2014-2016 epidemic in West Africa resulting in nearly 29,000 infections and over 11,000 fatalities. Dr Mark Feinberg, the head of IAVI, expressed grave concerns regarding the severity of the current situation, suggesting it could rival the scale of past epidemics if not addressed swiftly. He stated, “I think this is clearly threatening to be as severe an outbreak as that, if not even worse, and development of a vaccine, and other countermeasures, is clearly a priority.”
Médecins Sans Frontières (MSF) has echoed these sentiments, labelling the circumstances as “deeply alarming” and highlighting that the rapid increase in cases is unprecedented. The urgency is palpable, particularly as this outbreak emerged in a conflict zone where healthcare resources are severely limited.
The Challenge of Vaccine Development
Ebola presents unique challenges in vaccine development, primarily due to the existence of multiple virus species. Of the six known species, only three are responsible for outbreaks, and each requires a specific vaccine. Currently, an effective vaccine exists for the Zaire species, but Bundibugyo, the focus of the current outbreak, has only been documented twice previously, and no approved vaccine is available.
IAVI is developing a modified version of the Zaire vaccine specifically for Bundibugyo. Early tests in monkeys have shown promising results, with near-total protection observed. However, Dr Feinberg estimates that transitioning the vaccine to clinical trials could take an additional seven to nine months, although efforts are being made to expedite this process.
In parallel, pharmaceutical giant Moderna is applying its mRNA technology—successfully utilised against Covid-19—to create a vaccine for Bundibugyo. Stéphane Bancel, CEO of Moderna, assured that the company is committed to acting with urgency and scientific precision to deliver a viable solution swiftly.
Meanwhile, the University of Oxford is also leveraging its own vaccine technology, which played a pivotal role during the Covid pandemic, to produce a new Ebola vaccine expected to enter clinical trials within two to three months.
Diverse Approaches to Vaccine Technology
Each of the three vaccines being developed employs different methods to prepare the immune system to confront the Bundibugyo virus. IAVI’s approach utilises a live, harmless virus engineered to present the Ebola glycoprotein, effectively training the immune system to recognise and combat the actual virus.
Conversely, both the mRNA vaccine and the Oxford vaccine work by delivering snippets of genetic material that instruct the body to generate the Bundibugyo glycoprotein. This process primes the immune system to respond proactively to a genuine infection. However, the variances in technology may influence the degree of protection offered and the necessary number of doses, necessitating further testing through clinical trials.
The Coalition for Epidemic Preparedness Innovations (CEPI) is funding these critical research stages, with Dr Richard Hatchett, CEO of CEPI, emphasising the urgency of the situation. He stated, “With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease.”
A Call to Action from Global Health Leaders
The World Health Organization (WHO) has also weighed in on the situation, with Director-General Dr Tedros Adhanom Ghebreyesus highlighting the importance of a Bundibugyo vaccine to manage the current epidemic and enhance preparedness for future outbreaks. The global health community remains vigilant, and the rapid progression of vaccine development is a hopeful sign in combating this formidable disease.
Why it Matters
The ongoing development of vaccines against the Bundibugyo species of Ebola underscores a critical public health imperative. As outbreaks can escalate rapidly, the need for effective vaccines is paramount to prevent a potential health catastrophe akin to past epidemics. The collaborative efforts among research institutions, pharmaceutical companies, and global health organisations are vital in ensuring that the world is better equipped to face future health challenges, ultimately saving lives and mitigating the impact of infectious diseases.
